AAV Vector Encoding Urocortin 2 for Type I Diabetes Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating diseases related to increased paracrine polypeptide levels, such as Hemophilia B, lack regulated expression control and cardiovascular benefits, and require invasive protein infusions with short half-lives and high costs.
Innovation Solution
Administration of paracrine polypeptide-encoding nucleic acids or genes linked to transcriptional regulatory sequences using vectors like adeno-associated virus (AAV) serotypes, allowing for controlled expression and release of paracrine proteins into the bloodstream for therapeutic effects on conditions like heart disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If protein infusions are used to treat diseases like Hemophilia B, then the required protein levels can be achieved, but the treatment requires frequent administration due to short half-life and involves high costs
Solution Approach 1:
The invention delivers the gene encoding the therapeutic protein to the patient's cells in advance, enabling the body to produce the protein continuously without requiring repeated external administrations. The AAV vector carries the Factor IX gene to hepatocytes, where it integrates and establishes long-term expression capability.
Solution Approach 2:
The patient's own cells are engineered to produce the therapeutic protein autonomously. Once the AAV vector delivers the gene, the hepatocytes self-regulate to maintain appropriate protein levels through natural transcriptional and translational mechanisms, eliminating the need for continuous external intervention.
2Ease of manufacture
If non-regulated protein expression is used, then simple delivery is achieved, but optimal tailoring of transgene levels in serum cannot be enabled
Solution Approach 1:
The invention employs inducible promoters that allow dynamic control of gene expression levels. The tet-responsive promoter system enables the expression of Factor IX to be turned on or off, and adjusted to different levels, by administering or withholding doxycycline, providing real-time adaptability of protein production.
Solution Approach 2:
The regulated expression system allows monitoring and adjustment of protein levels through feedback control. By measuring serum Factor IX levels and adjusting doxycycline dosage accordingly, the system maintains optimal protein concentrations while preventing both deficiency and excessive expression.
3Reliability
If Factor IX gene is delivered without cardiovascular benefits, then Hemophilia B treatment is achieved, but heart disease cannot be treated
Solution Approach 1:
The AAV vector platform serves multiple therapeutic functions beyond Factor IX delivery. The same delivery system can accommodate genes for urocortin-2 (for heart failure), endothelin-receptor antagonists (for pulmonary hypertension), and other therapeutic proteins, making the platform universally applicable to various cardiovascular and metabolic diseases.
Data Source
AI summary
In alternative embodiments, the invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient against a disease, an infection or a condition responsive to an increased paracrine polypeptide level in vivo comprising: providing a paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence; or an expression vehicle, a vector, a recombinant virus, or equivalent, having contained therein a paracrine-encoding nucleic acid or gene, and the expression vehicle, vector, recombinant virus, or equivalent can express the paracrine-encoding nucleic acid or gene in a cell or in vivo; and administering or delivering the paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence, or the expression vehicle, vector, recombinant virus, or equivalent, to an individual or a patient in need thereof, thereby treating, ameliorating or protecting (preventing) the individual or patient against the disease, infection or condition responsive to an increased paracrine polypeptide level.